A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante  1     Valerie Pivorunas  2     James Butler  3     Naim Mahi  3     Nael M. Mostafa  3     Melanie Ruzek  3     James Fann  3     Feng Hong  3     Xiaohong Cao  4     Nizar Smaoui  4     Justin Wade Davis  4     Jasmina Kalabic  5     Alexandra Song  5     Heath M. Guay  5     Florian Rieder  6     Julian Panés  7     Jean-Frédéric Colombel  8    
1 University Hospitals Leuven, KU Leuven, Belgium
2 AbbVie Bioresearch Center, Worcester, United States
3 AbbVie Inc., North Chicago, United States
4 AbbVie Cambridge Research Center, Cambridge, United States
5 AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
6 Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, United States
7 Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
8 Icahn School of Medicine at Mt. Sinai, New York, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing